UPDATE: Stifel Nicolaus Raises PT to $33 on CareFusion Corporation on Margin Expansion

Loading...
Loading...
Stifel Nicolaus maintained CareFusion Corporation
CFN
with a Buy rating and raised the price target from $33.00 to $37.00. Stifel Nicolaus said, "Despite a shortfall in Dispensing (Pyxis) sales, CFN reported a solid quarter with some hard evidence that management's initiatives to improve revenue growth and drive operating efficiencies are starting to yield results. … But, in F3Q13, we project a y/y sales and EPS decline, due to the shifting of dispensing revenues into FY2014 (as the new Pyxis ES system launches) and off unusually difficult y/y Medical Systems comps. To us, all this sets the stage for what could be accelerated top and bottom line growth in FY2014, helped by a rebound in Dispensing, less negative than previously expected Infusion pump pricing, sustained growth in Procedural Solutions and continued efficiency measures." CareFusion Corporation closed at $31.83 on Thursday.
Posted In: Analyst ColorPrice TargetAnalyst RatingsStifel Nicolaus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...